 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Hybridon, Inc.
 |
Hybridon, Inc. |
 |
 |
 |
PROFILE |
 |
Antisense makes sense to Hybridon . . . and, antithetically, that's a good thing. Using antisense technology, which uses synthetic DNA and RNA to stop the body's production of disease-causing protein, along with antiangiogenesis technology, the firm develops drugs that have the potential to treat such diseases as HIV and cancer. Hybridon sold its synthetic RNA and DNA manufacturing operations, as well as its stake in MethylGene, a spinoff to which it licensed some of its antisense compounds. It has licensed antisense compounds targeting hepatitis B and the human papilloma virus to another spinoff, OriGenix Technologies. Founders Financial Group owns 30% of the firm, while Pecks Management Partners owns about 20%.
COMPETITION |
 |
Enzo Biochem, Inc. (ENZ)
Isis Pharmaceuticals, Inc. (ISIP)
SUGEN, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.60
1-Yr. Sales Growth: (91.8)%
Employees: 14
Revenue per employee: $42,857.14
KEY PEOPLE |
 |
Stephen R. Seiler
CEO
Robert G. Andersen
CFO
CONTACT INFO |
 |
345 Vassar St.
Cambridge, MA 02139
US
Phone: 617-679-5500
Fax: 617-679-5592
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |